RESUMEN
Peridotite and serpentinites can be used to sequester CO2 emissions through mineral carbonation. Olivine dissolution rate is directly proportional with temperature, presence of CO2, surface area of mineral particles and presence of ligands and is inversely proportional to pH. Olivine dissolution is better under air flow and increases seven times when rock-inhibiting fungus (Knufia petricola) is used. Olivine dissolution retards as silica layers form during reaction. Sonication, acoustic and concurrent grinding using various grinding medias have been used to artificially break these silica layers and achieve high magnesium extraction. Wet grinding using 50 wt.% ethanol enhanced CO2 uptake of dunite 6.9 times and CO2 uptake of harzburgite by 4.5 times. The best economical process is single-stage concurrent grinding at 130 bar, 185 °C, 15 wt.% solids and 50 wt.% grinding media (zirconia) using 0.64 M NaHCO3. Ratio of grinding media to feed should not be less than 3:1. Yield increases with temperature, pressure, time of reaction, pH and rpm and using additives and grinding media and reducing particle size. This review aims to investigate the progress from 1970s to 2021 on aqueous mineral carbonation of olivine and its naturally available rocks (harzburgite and dunite). This paper comprehensively reviews all aspects of olivine carbonation including olivine dissolution kinetics, effects of grinding and concurrent grinding, thermal activation of olivine feedstock (dunites and harzburgites) as well as chemistry of olivine mineral carbonation. The effects of different reaction parameters on the carbonation yield, role of mineral carbonation accelerators and costs of mineral carbonation process are discussed.
Asunto(s)
Dióxido de Carbono , Magnesio , Carbono , Carbonatos , Etanol , Compuestos de Hierro , Compuestos de Magnesio , Minerales , Silicatos , Dióxido de Silicio , AguaRESUMEN
BACKGROUND: Radiotherapy and cisplatin-based combination chemotherapy are accepted standard-of-care treatments for metastatic seminoma with excellent survival outcomes but with established short- and long-term morbidity. Carboplatin monotherapy may be a less toxic alternative; however early historic studies at AUC7 showed inferior outcomes. OBJECTIVES: To evaluate multi-institutional data on and toxicity and longer-term survival for metastatic seminoma patients treated with the single-agent carboplatin AUC10. METHODS: We undertook a multi-institutional analysis incorporating all men with the International Germ Cell Cancer Collaborative Group good-prognosis metastatic seminoma treated until 2018. Carboplatin AUC10 was given every 21 days. Toxicity, progression-free survival (PFS), disease-specific survival (DSS) and overall survival were noted. Variables predictive of progression were identified. RESULTS AND LIMITATIONS: 216 patients were treated. The three-year PFS rate was 96.5%, and five-year DSS was 98.3%. There were seven relapses, of which 5 were successfully salvaged with further chemotherapy ± surgery, and three non-seminoma-related deaths. There were no treatment-related deaths. Of 148/216 evaluable patients for toxicity, 37% and 27% suffered >/ = grade III neutropenia and thrombocytopenia, respectively. Twelve percent of patients needed a platelet or blood transfusion (or both). The incidence of febrile neutropenia was 5%. CONCLUSION: For metastatic seminoma, carboplatin AUC10 harbours a similar oncological efficacy to established therapies, with a low failure risk. The major acute toxicity was myelosuppression. Our study establishes carboplatin AUC10 as another standard-of-care treatment option for good-prognosis metastatic seminoma, with a potentially lower toxicity profile than other therapies.
Asunto(s)
Antineoplásicos , Neoplasias de Células Germinales y Embrionarias , Neoplasias Primarias Secundarias , Seminoma , Neoplasias Testiculares , Antineoplásicos/uso terapéutico , Carboplatino , Humanos , Masculino , Recurrencia Local de Neoplasia/patología , Estadificación de Neoplasias , Neoplasias de Células Germinales y Embrionarias/tratamiento farmacológico , Neoplasias Primarias Secundarias/patología , Seminoma/tratamiento farmacológico , Seminoma/patología , Neoplasias Testiculares/patología , Reino UnidoRESUMEN
OBJECTIVE: A locally advanced Gleason 4 + 4 prostate cancer patient who was on self-medication with intermittent anti-androgen monotherapy (iAAm) over 14 years suggested that raised testosterone was not dangerous and this suggestion needed investigating. PATIENTS: Others who were on AA continuously were recruited to ongoing audit of intermittent hormone therapy (IHT) and iAAm outcomes were compared with intermittent LHRH therapy (iLHRH or iMAB). RESULTS: Between 1994 and 2007, 111 patients sought IHT because of side effects of treatment. Forty-two M0 patients received IHT with iLHRHm or iMAB and 33 received iAAm (31 of these were M0). PSA nadir below 4 was necessary for entry. Overall survival was 87, 72 and 67% with iAAm and 73, 56 and 43% with iLHRH/MAB at 5, 8 and 10 years respectively. Overall survival was 61, 55 and 33% continued on iAAm and 56, 41, and 32% on iLHRH/MAB at 5, 8, and 10 years respectively. Multivariable analysis and matched case control analysis confirm that the maintenance of advantage for iAAm Testosterone levels in patients on iAAm compared to iLHRH therapy was more intense throughout treatment. CONCLUSION: These results complement recent progress in using bipolar androgen therapy to reverse castration resistance and add to the increasing acceptance that controlled testosterone exposure might be relevant in hormone-naïve patients.
Asunto(s)
Antagonistas de Andrógenos/administración & dosificación , Antineoplásicos Hormonales/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Hormona Liberadora de Gonadotropina/agonistas , Hipófisis/efectos de los fármacos , Neoplasias de la Próstata/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Antagonistas de Andrógenos/efectos adversos , Antineoplásicos Hormonales/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Esquema de Medicación , Hormona Liberadora de Gonadotropina/metabolismo , Humanos , Calicreínas/sangre , Estimación de Kaplan-Meier , Modelos Lineales , Masculino , Auditoría Médica , Persona de Mediana Edad , Análisis Multivariante , Clasificación del Tumor , Estadificación de Neoplasias , Oportunidad Relativa , Hipófisis/metabolismo , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/mortalidad , Neoplasias de la Próstata/patología , Factores de Tiempo , Resultado del TratamientoRESUMEN
OBJECTIVE: Metastatic seminoma is a highly curable disease. Standard treatment comprises of combination chemotherapy. The short- and long-term toxicities of this treatment are increasingly recognised and the possibility of over treatment in such a curable disease should be considered. We have therefore assessed the use of single agent carboplatin at a dose of AUC 10 in patients with good prognosis metastatic seminoma. MATERIALS AND METHODS: Patients with good prognosis metastatic seminoma treated with carboplatin (AUC 10) were identified at our institution and affiliated institutions. Treatment was three weekly for a total of three or four cycles. Outcome and toxicities were analysed. RESULTS: With a median follow-up of 36 months, 61 patients in total were treated with carboplatin AUC 10, all good prognosis by the IGCCCG criteria. Forty-eight percent had stage IIA/IIB disease and 52% had greater than stage IIB disease. Thirty-one patients (51%) had a complete response following treatment. Three-year survival was 96.3% with a three-year progression free survival of 93.2%. The main treatment toxicity was haematological with 46% having grade 3, 24% having grade 4 neutropenia and 54% experiencing grade 3/4 thrombocytopenia. There were no treatment related deaths. CONCLUSION: Single agent carboplatin at a dose of AUC 10 is an effective treatment for good prognosis metastatic seminoma. The outcome compares favourably to previously published outcomes of combination chemotherapy. Although haematological toxicity is a concern, single agent carboplatin treatment for good prognosis metastatic seminoma could be considered a treatment option and is associated with less toxicity than combination regimens currently used.
Asunto(s)
Antineoplásicos/uso terapéutico , Carboplatino/uso terapéutico , Seminoma/tratamiento farmacológico , Neoplasias Testiculares/tratamiento farmacológico , Adulto , Anciano , Supervivencia sin Enfermedad , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Neutropenia/inducido químicamente , Estudios Retrospectivos , Seminoma/patología , Neoplasias Testiculares/patología , Trombocitopenia/inducido químicamente , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND AND OBJECTIVES: Cisplatin-based chemotherapy is standard care for metastatic transitional cell carcinoma (TCC) of the urinary tract. However it is not appropriate for all patients, particularly those with poor renal function. There is no clear consensus on the optimal regimen for these individuals or for those after cisplatin failure. Here we present data using mitomycin, 5-fluorouracil, and irinotecan (MFI) in these patients. MATERIALS AND METHODS: Patients with TCC, who had either received cisplatin-based chemotherapy previously or who were not deemed fit for cisplatin therapy (creatinine clearance was less than 60 ml/min) were eligible for treatment with the experimental combination chemotherapy regimen MFI. RESULTS: Thirty-six patients were treated with MFI between 2001 and 2004. Overall response rate was 19% and median overall survival (OS) was 5.4 months (95% CI 3.3-8.4 months). The response rate and overall survival in both groups was 19% and 5.4 months, respectively, (95% CI 2.9-7.1 months) in the pretreated and 2.5- 9.3 months in the untreated. The most common toxicity was malaise (grade 3 or 4 = 28%). CONCLUSIONS: MFI appear to be a combination which requires further investigation in patients where cisplatin and gemcitabine are not applicable.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Transicionales/tratamiento farmacológico , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Neoplasias Urológicas/tratamiento farmacológico , Anciano , Biopsia , Camptotecina/administración & dosificación , Camptotecina/análogos & derivados , Carcinoma de Células Transicionales/mortalidad , Cisplatino/uso terapéutico , Femenino , Fluorouracilo/administración & dosificación , Humanos , Irinotecán , Masculino , Persona de Mediana Edad , Mitomicina/administración & dosificación , Factores de Tiempo , Resultado del Tratamiento , Neoplasias de la Vejiga Urinaria/mortalidadRESUMEN
Interferon-ß (IFN-ß) is widely used to treat multiple sclerosis (MS), and its efficacy was demonstrated in the setting of experimental autoimmune encephalomyelitis (EAE), an animal model of MS; however, IFN-ß is not effective in treating all cases of MS. Here, we demonstrate that signaling by IFNAR (the shared receptor for IFN-α and IFN-ß) on macrophages inhibits activation of Rac1 and the generation of reactive oxygen species (ROS) through suppressor of cytokine signaling 1 (SOCS1). The inhibition of Rac1 activation and ROS generation suppressed the activity of the Nod-like receptor (NLR) family, pyrin domain-containing 3 (NLRP3) inflammasome, which resulted in attenuated EAE pathogenicity. We further found that two subsets of EAE could be defined on the basis of their dependency on the NLRP3 inflammasome and that IFN-ß was not an effective therapy when EAE was induced in an NLRP3 inflammasome-independent fashion. Thus, our study demonstrates a previously uncharacterized signaling pathway that is involved in the suppression of EAE by IFN-ß and characterizes NLRP3-independent EAE, which cannot be treated with IFN-ß.
Asunto(s)
Proteínas Portadoras/fisiología , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Inflamasomas/fisiología , Interferón beta/uso terapéutico , Receptor de Interferón alfa y beta/fisiología , Animales , Proteínas Reguladoras de la Apoptosis , Proteínas Adaptadoras de Señalización CARD , Linfocitos T CD4-Positivos/trasplante , Proteínas Portadoras/genética , Caspasa 1/fisiología , Proteínas del Citoesqueleto/deficiencia , Modelos Animales de Enfermedad , Encefalomielitis Autoinmune Experimental/inmunología , Encefalomielitis Autoinmune Experimental/fisiopatología , Activación Enzimática , Regulación de la Expresión Génica/efectos de los fármacos , Interferon beta-1b , Interleucina-1beta/biosíntesis , Interleucina-1beta/genética , Macrófagos/fisiología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Transgénicos , Proteína con Dominio Pirina 3 de la Familia NLR , Neuropéptidos/antagonistas & inhibidores , Neuropéptidos/fisiología , Proteínas Proto-Oncogénicas c-vav/antagonistas & inhibidores , Proteínas Proto-Oncogénicas c-vav/fisiología , Especies Reactivas de Oxígeno/metabolismo , Receptor de Interferón alfa y beta/deficiencia , Proteínas Recombinantes/uso terapéutico , Proteína 1 Supresora de la Señalización de Citocinas , Proteínas Supresoras de la Señalización de Citocinas/antagonistas & inhibidores , Proteínas Supresoras de la Señalización de Citocinas/fisiología , Proteínas de Unión al GTP rac/antagonistas & inhibidores , Proteínas de Unión al GTP rac/fisiología , Proteína de Unión al GTP rac1RESUMEN
We found that absence of osteopontin (OPN) in immunocompromised Rag2(-/-) mice, which lack T and B cells, made the mice extremely susceptible to an opportunistic fungus Pneumocystis, although immunocompetent OPN-deficient mice could clear Pneumocystis as well as wild-type mice. OPN has been studied as an extracellular protein, and the role of an intracellular isoform of OPN (iOPN) is still largely unknown. In this study, we elucidated the mechanism by which iOPN was involved in antifungal innate immunity. First, iOPN was essential for cluster formation of fungal receptors that detect Pneumocystis, including dectin-1, TLR2, and mannose receptor. Second, iOPN played a role as an adaptor molecule in TLR2 and dectin-1 signaling pathways and mediated ERK activation and cytokine production by zymosan, which simultaneously activates TLR2 and dectin-1 pathways. Third, iOPN enhanced phagocytosis and clearance of Pneumocystis. Our study suggests the critical involvement of iOPN in antifungal innate immunity.
Asunto(s)
Inmunidad Innata , Líquido Intracelular/inmunología , Líquido Intracelular/microbiología , Osteopontina/fisiología , Infecciones por Pneumocystis/inmunología , Infecciones por Pneumocystis/microbiología , Pneumocystis/crecimiento & desarrollo , Pneumocystis/inmunología , Inmunidad Adaptativa/genética , Animales , Membrana Celular/inmunología , Membrana Celular/metabolismo , Membrana Celular/microbiología , Predisposición Genética a la Enfermedad , Inmunidad Innata/genética , Líquido Intracelular/metabolismo , Lectinas Tipo C , Proteínas de la Membrana/fisiología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Proteínas del Tejido Nervioso/fisiología , Osteopontina/deficiencia , Osteopontina/metabolismo , Infecciones por Pneumocystis/prevención & control , Receptores de Reconocimiento de Patrones/biosíntesis , Receptores de Reconocimiento de Patrones/metabolismo , Transducción de Señal/genética , Transducción de Señal/inmunología , Receptor Toll-Like 2/fisiologíaRESUMEN
Cryptococcus neoformans is a facultative intracellular opportunistic pathogen and the leading cause of fungal meningitis in humans. In the absence of a protective cellular immune response, the inhalation of C. neoformans cells or spores results in pulmonary infection. C. neoformans cells produce a polysaccharide capsule composed predominantly of glucuronoxylomannan, which constitutes approximately 90% of the capsular material. In the lungs, surfactant protein A (SP-A) and SP-D contribute to immune defense by facilitating the aggregation, uptake, and killing of many microorganisms by phagocytic cells. We hypothesized that SP-D plays a role in C. neoformans pathogenesis by binding to and enhancing the phagocytosis of the yeast. Here, the abilities of SP-D to bind to and facilitate the phagocytosis and survival of the wild-type encapsulated strain H99 and the cap59Delta mutant hypocapsular strain are assessed. SP-D binding to cap59Delta mutant cells was approximately sixfold greater than binding to wild-type cells. SP-D enhanced the phagocytosis of cap59Delta cells by approximately fourfold in vitro. To investigate SP-D binding in vivo, SP-D(-/-) mice were intranasally inoculated with Alexa Fluor 488-labeled cap59Delta or H99 cells. By confocal microscopy, a greater number of phagocytosed C. neoformans cells in wild-type mice than in SP-D(-/-) mice was observed, consistent with in vitro data. Interestingly, SP-D protected C. neoformans cells against macrophage-mediated defense mechanisms in vitro, as demonstrated by an analysis of fungal viability using a CFU assay. These findings provide evidence that C. neoformans subverts host defense mechanisms involving surfactant, establishing a novel virulence paradigm that may be targeted for therapy.
Asunto(s)
Cryptococcus neoformans/inmunología , Macrófagos/microbiología , Viabilidad Microbiana , Fagocitosis , Proteína D Asociada a Surfactante Pulmonar/inmunología , Animales , Línea Celular , Recuento de Colonia Microbiana , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Unión Proteica , Proteína D Asociada a Surfactante Pulmonar/deficiencia , Proteína D Asociada a Surfactante Pulmonar/metabolismoRESUMEN
Molecular biologists use hidden Markov models (HMMs) as a popular tool to statistically describe biological sequence families. This statistical description can then be used for sensitive and selective database scanning, e.g., new protein sequences are compared with a set of HMMs to detect functional similarities. Efficient dynamic-programming algorithms exist for solving this problem; however, current solutions still require significant scan times. These scan time requirements are likely to become even more severe due to the rapid growth in the size of these databases. This paper shows how reconfigurable architectures can be used to derive an efficient fine-grained parallelization of the dynamic programming calculation. We describe how this technique leads to significant runtime savings for HMM database scanning on a standard off-the-shelf field-programmable gate array (FPGA).
Asunto(s)
Biología Computacional/métodos , Cadenas de Markov , Reconocimiento de Normas Patrones Automatizadas/métodos , Análisis de Secuencia de Proteína/métodos , Algoritmos , Alineación de Secuencia/métodosRESUMEN
AIMS: To see whether macrosomic infants have different morbidity according to maternal screening results for gestational diabetes mellitus (GDM) and ethnicity. METHODS: After excluding infants of women with diabetes, the National Women's Hospital database identified 134 infants who were delivered in 2003 and weighed >or= 4500 g. Case notes were reviewed to record risk factors for macrosomia, delivery details and neonatal morbidity. Outcomes were analysed according to screening results for GDM and compared between Polynesian and Asian women. RESULTS: Body mass index (BMI) was calculated in 29% of women, and GDM screening was undertaken in 51%. Infants of women who had a screening glucose < 7.2 mmol/L compared to >or= 7.8 mmol/L had lower rates of admission to the neonatal intensive care unit (NICU) (6.4 vs 28.6%, P=0.049), had less respiratory distress (3.2 vs 23.8%P=0.033) and display a trend to less require intravenous dextrose (6.4 vs 23.8%P=0.10). Maternal BMI was lower in Asian (26.5 +/- 4.4 kg/m(2)) compared to Polynesian women (35.2 +/- 8.1 kg/m(2), P=0.008). More Asian women had a Caesarean delivery (73.3 vs 25%P<0.001) and their infants were more likely to be admitted to NICU (33.3 vs 7.7%P=0.02), require intravenous dextrose (20 vs 1.9%P=0.03) and have respiratory distress (26.7 vs 3.8%P=0.02). CONCLUSION: Risk factors for macrosomia are not assessed adequately, which may contribute to morbidity. Using a birthweight >or= 4500 g to define macrosomia is associated with disparate morbidity between ethnicities that have different body compositions.
Asunto(s)
Peso al Nacer/fisiología , Diabetes Gestacional , Macrosomía Fetal/epidemiología , Adulto , Pueblo Asiatico , Índice de Masa Corporal , Etnicidad , Femenino , Macrosomía Fetal/etnología , Humanos , Recién Nacido , Morbilidad , Nativos de Hawái y Otras Islas del Pacífico , Nueva Zelanda , Embarazo , Resultado del Embarazo , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Población BlancaRESUMEN
A family history of disease is a strong risk factor for testicular germ cell tumour (TGCT). In order to identify the location of putative TGCT susceptibility gene(s) we conducted a linkage search in 237 pedigrees with two or more cases of TGCT. One hundred and seventy-nine pedigrees were evaluated genome-wide with an average inter-marker distance of 10 cM. An additional 58 pedigrees were used to more intensively investigate several genomic regions of interest. Genetic linkage analysis was performed with the ALLEGRO software using two model-based parametric analyses and a non-parametric analysis. Six genomic regions on chromosomes 2p23, 3p12, 3q26, 12p13-q21, 18q21-q23 and Xq27 showed heterogeneity LOD (HLOD) scores of greater than 1, with a maximum HLOD of 1.94 at 3q26. Genome-wide simulation studies indicate that the observed number of HLOD peaks greater than one does not differ significantly from that expected by chance. A TGCT locus at Xq27 has been previously reported. Of the 237 pedigrees examined in this study, 66 were previously unstudied at Xq27, no evidence for linkage to this region was observed in this new pedigree set. Overall, the results indicate that no single major locus can account for the majority of the familial aggregation of TGCT, and suggests that multiple susceptibility loci with weak effects contribute to the disease.
Asunto(s)
Ligamiento Genético/genética , Predisposición Genética a la Enfermedad/genética , Genoma Humano/genética , Neoplasias de Células Germinales y Embrionarias/genética , Neoplasias Testiculares/genética , Mapeo Cromosómico , Cromosomas Humanos X/genética , Femenino , Heterogeneidad Genética , Humanos , Escala de Lod , Masculino , LinajeRESUMEN
OBJECTIVE: To identify a novel nongenomic progesterone receptor (PR), PR-M, in T47D-Y breast cancer cells lacking genomic PR expression. METHODS: Immunofluorescent staining of T47D and T47D-Y breast cancer cells with selective anti-PR antibodies and ligand binding. Transient transfection of breast cancer cells with a cDNA expressing PR-M with a carboxy terminal green fluorescent protein. RESULTS: In the T47D-Y cell line, lacking expression of genomic PR, plasma membrane-bound and intracellular PR(s) are identified with anti-PR antibodies directed to the hormone-binding domain but not with an antibody directed to the amino terminus. A plasma membrane PR is also evident by immunofluorescent ligand binding. Expression of a novel truncated PR (PR-M) tagged with green fluorescent protein showed intracellular localization. CONCLUSIONS: These studies support the expression of a novel, truncated PR (PR-M) in a breast cancer cell line known to lack expression of genomic PR. This observation raises the possibility of progesterone action in breast cancer cells classically considered nonresponsive due to lack of genomic PR expression.
Asunto(s)
Neoplasias de la Mama/metabolismo , Receptores de Progesterona/metabolismo , Animales , Neoplasias de la Mama/genética , Línea Celular Tumoral , Membrana Celular/metabolismo , Femenino , Técnica del Anticuerpo Fluorescente , Expresión Génica , Proteínas Fluorescentes Verdes/genética , Humanos , Ratones , Conejos , Receptores de Progesterona/genética , Receptores de Progesterona/inmunología , Transfección , Células Tumorales CultivadasRESUMEN
Microbial pathogens have evolved diverse strategies to modulate the host cell cytoskeleton to achieve a productive infection and have proven instrumental for unraveling the molecular machinery that regulates actin polymerization. Here we uncover a mechanism for Shigella flexneri-induced actin comet tail elongation that links Abl family kinases to N-WASP-dependent actin polymerization. We show that the Abl kinases are required for Shigella actin comet tail formation, maximal intracellular motility, and cell-to-cell spread. Abl phosphorylates N-WASP, a host cell protein required for actin comet tail formation, and mutation of the Abl phosphorylation sites on N-WASP impairs comet tail elongation. Furthermore, we show that defective comet tail formation in cells lacking Abl kinases is rescued by activated forms of N-WASP. These data demonstrate for the first time that the Abl kinases play a role in the intracellular motility and intercellular dissemination of Shigella and uncover a new role for Abl kinases in the regulation of pathogen motility.
Asunto(s)
Actinas/química , Actinas/metabolismo , Proteínas Proto-Oncogénicas c-abl/metabolismo , Animales , Sitios de Unión , Células CACO-2 , Bovinos , Línea Celular , Células Cultivadas , Citoesqueleto/metabolismo , Humanos , Técnicas In Vitro , Ratones , Ratones Noqueados , Fosforilación , Proteínas Proto-Oncogénicas c-abl/deficiencia , Proteínas Proto-Oncogénicas c-abl/genética , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Shigella flexneri/patogenicidad , Tirosina/químicaAsunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Camptotecina/análogos & derivados , Carcinoma de Células Renales/tratamiento farmacológico , Neoplasias Renales/tratamiento farmacológico , Camptotecina/administración & dosificación , Carcinoma de Células Renales/mortalidad , Cisplatino/administración & dosificación , Citocinas/uso terapéutico , Resistencia a Antineoplásicos , Humanos , Irinotecán , Neoplasias Renales/mortalidad , Mitomicina/administración & dosificación , Metástasis de la Neoplasia , PronósticoRESUMEN
The development of many organs, including the lung, depends upon a process known as branching morphogenesis, in which a simple epithelial bud gives rise to a complex tree-like system of tubes specialized for the transport of gas or fluids. Previous studies on lung development have highlighted a role for fibroblast growth factors (FGFs), made by the mesodermal cells, in promoting the proliferation, budding, and chemotaxis of the epithelial endoderm. Here, by using a three-dimensional culture system, we provide evidence for a novel role for Netrins, best known as axonal guidance molecules, in modulating the morphogenetic response of lung endoderm to exogenous FGFs. This effect involves inhibition of localized changes in cell shape and phosphorylation of the intracellular mitogen-activated protein kinase(s) (ERK1/2, for extracellular signal-regulated kinase-1 and -2), elicited by exogenous FGFs. The temporal and spatial expression of netrin 1, netrin 4, and Unc5b genes and the localization of Netrin-4 protein in vivo suggest a model in which Netrins in the basal lamina locally modulate and fine-tune the outgrowth and shape of emergent epithelial buds.
Asunto(s)
Endodermo/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Pulmón/embriología , Factores de Crecimiento Nervioso/metabolismo , Animales , Línea Celular , Tamaño de la Célula/efectos de los fármacos , Cartilla de ADN , Endodermo/efectos de los fármacos , Factores de Crecimiento de Fibroblastos/metabolismo , Humanos , Immunoblotting , Inmunohistoquímica , Hibridación in Situ , Pulmón/metabolismo , Ratones , Ratones Endogámicos ICR , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Modelos Biológicos , Morfogénesis , Factores de Crecimiento Nervioso/farmacología , Netrina-1 , Netrinas , Transfección , Proteínas Supresoras de TumorRESUMEN
The aim of this study was to isolate and identify antigenic peptides associated with HLA class I molecules on a bladder tumour cell line. HLA-A1 molecules were purified using an immunobead-purification technique and following elution of nonapeptides associated with the complex, their HPLC profile was determined by Tandem mass spectrometry (MS/MS). Three peptides were identified namely: (1) P991 (VTDPGNLLY); (2) P1041.5 (LTDLGFLVY), and (3) P1057.7 (LTDPHLLSY); these sequences matched elements of hepatitis B, MAGE1-A1 and herpes simplex viruses. These antigens had half-lives of approximately 120 min which is within the theoretical range of such short peptides. These results indicate that identification of MHC-associated peptides is possible without using an assay for cytotoxic T cells. Although this approach was applied on a relatively small scale, broader applications can be foreseen.